Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Respiratory Panel Testing Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, 2018–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Specimen Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
6.3.1. Viruses
6.3.1.1. Adenovirus
6.3.1.2. Severe Acute Respiratory Syndrome
6.3.1.3. RSV
6.3.1.4. Human Metapneumovirus
6.3.1.5. Rhinovirus/Enterovirus
6.3.1.6. Parainfluenza Virus
6.3.1.7. Flu A
6.3.1.8. Others
6.3.2. Bacteria
6.3.2.1. Mycoplasma Pneumoniae
6.3.2.2. Chlamydophila Pneumonia
6.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type

7. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Panel Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Panel Type

8. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
8.3.1. Hospital Point-of-Care testing
8.3.2. Reference Labs
8.3.3. Hospitals
8.3.4. Others
8.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by End-user

9. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region
9.2.1. Europe
9.2.2. Middle East & Africa
9.3. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Country/Region

10. Europe Respiratory Panel Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
10.2.1. Viruses
10.2.1.1. Adenovirus
10.2.1.2. Severe Acute Respiratory Syndrome
10.2.1.3. RSV
10.2.1.4. Human Metapneumovirus
10.2.1.5. Rhinovirus/Enterovirus
10.2.1.6. Parainfluenza Virus
10.2.1.7. Flu A
10.2.1.8. Others
10.2.2. Bacteria
10.2.2.1. Mycoplasma Pneumoniae
10.2.2.2. Chlamydophila Pneumonia
10.3. Market Value Forecast, by Panel Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospital Point-of-Care testing
10.4.2. Ref Laboratories
10.4.3. Hospitals
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.1.1.1. Viruses
10.5.1.1.1.1. Adenovirus
10.5.1.1.1.2. Severe Acute Respiratory Syndrome
10.5.1.1.1.3. RSV
10.5.1.1.1.4. Human Metapneumovirus
10.5.1.1.1.5. Rhinovirus/Enterovirus
10.5.1.1.1.6. Parainfluenza Virus
10.5.1.1.1.7. Flu A
10.5.1.1.1.8. Others
10.5.1.1.2. Bacteria
10.5.1.1.2.1. Mycoplasma Pneumoniae
10.5.1.1.2.2. Chlamydophila Pneumonia
10.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospital Point-of-Care testing
10.5.1.3.2. Ref Laboratories
10.5.1.3.3. Hospitals
10.5.1.3.4. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.2.1.1. Viruses
10.5.2.1.1.1. Adenovirus
10.5.2.1.1.2. Severe Acute Respiratory Syndrome
10.5.2.1.1.3. RSV
10.5.2.1.1.4. Human Metapneumovirus
10.5.2.1.1.5. Rhinovirus/Enterovirus
10.5.2.1.1.6. Parainfluenza Virus
10.5.2.1.1.7. Flu A
10.5.2.1.1.8. Others
10.5.2.1.2. Bacteria
10.5.2.1.2.1. Mycoplasma Pneumoniae
10.5.2.1.2.2. Chlamydophila Pneumonia
10.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospital Point-of-Care testing
10.5.2.3.2. Ref Laboratories
10.5.2.3.3. Hospitals
10.5.2.3.4. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.3.1.1. Viruses
10.5.3.1.1.1. Adenovirus
10.5.3.1.1.2. Severe Acute Respiratory Syndrome
10.5.3.1.1.3. RSV
10.5.3.1.1.4. Human Metapneumovirus
10.5.3.1.1.5. Rhinovirus/Enterovirus
10.5.3.1.1.6. Parainfluenza Virus
10.5.3.1.1.7. Flu A
10.5.3.1.1.8. Others
10.5.3.1.2. Bacteria
10.5.3.1.2.1. Mycoplasma Pneumoniae
10.5.3.1.2.2. Chlamydophila Pneumonia
10.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospital Point-of-Care testing
10.5.3.3.2. Ref Laboratories
10.5.3.3.3. Hospitals
10.5.3.3.4. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.4.1.1. Viruses
10.5.4.1.1.1. Adenovirus
10.5.4.1.1.2. Severe Acute Respiratory Syndrome
10.5.4.1.1.3. RSV
10.5.4.1.1.4. Human Metapneumovirus
10.5.4.1.1.5. Rhinovirus/Enterovirus
10.5.4.1.1.6. Parainfluenza Virus
10.5.4.1.1.7. Flu A
10.5.4.1.1.8. Others
10.5.4.1.2. Bacteria
10.5.4.1.2.1. Mycoplasma Pneumoniae
10.5.4.1.2.2. Chlamydophila Pneumonia
10.5.4.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospital Point-of-Care testing
10.5.4.3.2. Ref Laboratories
10.5.4.3.3. Hospitals
10.5.4.3.4. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.5.1.1. Viruses
10.5.5.1.1.1. Adenovirus
10.5.5.1.1.2. Severe Acute Respiratory Syndrome
10.5.5.1.1.3. RSV
10.5.5.1.1.4. Human Metapneumovirus
10.5.5.1.1.5. Rhinovirus/Enterovirus
10.5.5.1.1.6. Parainfluenza Virus
10.5.5.1.1.7. Flu A
10.5.5.1.1.8. Others
10.5.5.1.2. Bacteria
10.5.5.1.2.1. Mycoplasma Pneumoniae
10.5.5.1.2.2. Chlamydophila Pneumonia
10.5.5.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospital Point-of-Care testing
10.5.5.3.2. Ref Laboratories
10.5.5.3.3. Hospitals
10.5.5.3.4. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.6.1.1. Viruses
10.5.6.1.1.1. Adenovirus
10.5.6.1.1.2. Severe Acute Respiratory Syndrome
10.5.6.1.1.3. RSV
10.5.6.1.1.4. Human Metapneumovirus
10.5.6.1.1.5. Rhinovirus/Enterovirus
10.5.6.1.1.6. Parainfluenza Virus
10.5.6.1.1.7. Flu A
10.5.6.1.1.8. Others
10.5.6.1.2. Bacteria
10.5.6.1.2.1. Mycoplasma Pneumoniae
10.5.6.1.2.2. Chlamydophila Pneumonia
10.5.6.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospital Point-of-Care testing
10.5.6.3.2. Ref Laboratories
10.5.6.3.3. Hospitals
10.5.6.3.4. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.7.1.1. Viruses
10.5.7.1.1.1. Adenovirus
10.5.7.1.1.2. Severe Acute Respiratory Syndrome
10.5.7.1.1.3. RSV
10.5.7.1.1.4. Human Metapneumovirus
10.5.7.1.1.5. Rhinovirus/Enterovirus
10.5.7.1.1.6. Parainfluenza Virus
10.5.7.1.1.7. Flu A
10.5.7.1.1.8. Others
10.5.7.1.2. Bacteria
10.5.7.1.2.1. Mycoplasma Pneumoniae
10.5.7.1.2.2. Chlamydophila Pneumonia
10.5.7.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospital Point-of-Care testing
10.5.7.3.2. Ref Laboratories
10.5.7.3.3. Hospitals
10.5.7.3.4. Others
10.5.8. Sweden
10.5.8.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.8.1.1. Viruses
10.5.8.1.1.1. Adenovirus
10.5.8.1.1.2. Severe Acute Respiratory Syndrome
10.5.8.1.1.3. RSV
10.5.8.1.1.4. Human Metapneumovirus
10.5.8.1.1.5. Rhinovirus/Enterovirus
10.5.8.1.1.6. Parainfluenza Virus
10.5.8.1.1.7. Flu A
10.5.8.1.1.8. Others
10.5.8.1.2. Bacteria
10.5.8.1.2.1. Mycoplasma Pneumoniae
10.5.8.1.2.2. Chlamydophila Pneumonia
10.5.8.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospital Point-of-Care testing
10.5.8.3.2. Ref Laboratories
10.5.8.3.3. Hospitals
10.5.8.3.4. Others
10.5.9. Denmark
10.5.9.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.9.1.1. Viruses
10.5.9.1.1.1. Adenovirus
10.5.9.1.1.2. Severe Acute Respiratory Syndrome
10.5.9.1.1.3. RSV
10.5.9.1.1.4. Human Metapneumovirus
10.5.9.1.1.5. Rhinovirus/Enterovirus
10.5.9.1.1.6. Parainfluenza Virus
10.5.9.1.1.7. Flu A
10.5.9.1.1.8. Others
10.5.9.1.2. Bacteria
10.5.9.1.2.1. Mycoplasma Pneumoniae
10.5.9.1.2.2. Chlamydophila Pneumonia
10.5.9.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017–2031
10.5.9.3.1. Hospital Point-of-Care testing
10.5.9.3.2. Ref Laboratories
10.5.9.3.3. Hospitals
10.5.9.3.4. Others
10.5.10. Finland
10.5.10.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.10.1.1. Viruses
10.5.10.1.1.1. Adenovirus
10.5.10.1.1.2. Severe Acute Respiratory Syndrome
10.5.10.1.1.3. RSV
10.5.10.1.1.4. Human Metapneumovirus
10.5.10.1.1.5. Rhinovirus/Enterovirus
10.5.10.1.1.6. Parainfluenza Virus
10.5.10.1.1.7. Flu A
10.5.10.1.1.8. Others
10.5.10.1.2. Bacteria
10.5.10.1.2.1. Mycoplasma Pneumoniae
10.5.10.1.2.2. Chlamydophila Pneumonia
10.5.10.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospital Point-of-Care testing
10.5.10.3.2. Ref Laboratories
10.5.10.3.3. Hospitals
10.5.10.3.4. Others
10.5.11. Norway
10.5.11.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.11.1.1. Viruses
10.5.11.1.1.1. Adenovirus
10.5.11.1.1.2. Severe Acute Respiratory Syndrome
10.5.11.1.1.3. RSV
10.5.11.1.1.4. Human Metapneumovirus
10.5.11.1.1.5. Rhinovirus/Enterovirus
10.5.11.1.1.6. Parainfluenza Virus
10.5.11.1.1.7. Flu A
10.5.11.1.1.8. Others
10.5.11.1.2. Bacteria
10.5.11.1.2.1. Mycoplasma Pneumoniae
10.5.11.1.2.2. Chlamydophila Pneumonia
10.5.11.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospital Point-of-Care testing
10.5.11.3.2. Ref Laboratories
10.5.11.3.3. Hospitals
10.5.11.3.4. Others
10.5.12. Switzerland
10.5.12.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.12.1.1. Viruses
10.5.12.1.1.1. Adenovirus
10.5.12.1.1.2. Severe Acute Respiratory Syndrome
10.5.12.1.1.3. RSV
10.5.12.1.1.4. Human Metapneumovirus
10.5.12.1.1.5. Rhinovirus/Enterovirus
10.5.12.1.1.6. Parainfluenza Virus
10.5.12.1.1.7. Flu A
10.5.12.1.1.8. Others
10.5.12.1.2. Bacteria
10.5.12.1.2.1. Mycoplasma Pneumoniae
10.5.12.1.2.2. Chlamydophila Pneumonia
10.5.12.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospital Point-of-Care testing
10.5.12.3.2. Ref Laboratories
10.5.12.3.3. Hospitals
10.5.12.3.4. Others
10.5.13. Austria
10.5.13.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.13.1.1. Viruses
10.5.13.1.1.1. Adenovirus
10.5.13.1.1.2. Severe Acute Respiratory Syndrome
10.5.13.1.1.3. RSV
10.5.13.1.1.4. Human Metapneumovirus
10.5.13.1.1.5. Rhinovirus/Enterovirus
10.5.13.1.1.6. Parainfluenza Virus
10.5.13.1.1.7. Flu A
10.5.13.1.1.8. Others
10.5.13.1.2. Bacteria
10.5.13.1.2.1. Mycoplasma Pneumoniae
10.5.13.1.2.2. Chlamydophila Pneumonia
10.5.13.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospital Point-of-Care testing
10.5.13.3.2. Ref Laboratories
10.5.13.3.3. Hospitals
10.5.13.3.4. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.14.1.1. Viruses
10.5.14.1.1.1. Adenovirus
10.5.14.1.1.2. Severe Acute Respiratory Syndrome
10.5.14.1.1.3. RSV
10.5.14.1.1.4. Human Metapneumovirus
10.5.14.1.1.5. Rhinovirus/Enterovirus
10.5.14.1.1.6. Parainfluenza Virus
10.5.14.1.1.7. Flu A
10.5.14.1.1.8. Others
10.5.14.1.2. Bacteria
10.5.14.1.2.1. Mycoplasma Pneumoniae
10.5.14.1.2.2. Chlamydophila Pneumonia
10.5.14.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospital Point-of-Care testing
10.5.14.3.2. Ref Laboratories
10.5.14.3.3. Hospitals
10.5.14.3.4. Others
10.6. Market Attractiveness Analysis
10.6.1. By Specimen Type
10.6.2. By Panel Type
10.6.3. By End-user
10.6.4. By Country/Sub-region

11. Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
11.2.1. Viruses
11.2.1.1. Adenovirus
11.2.1.2. Severe Acute Respiratory Syndrome
11.2.1.3. RSV
11.2.1.4. Human Metapneumovirus
11.2.1.5. Rhinovirus/Enterovirus
11.2.1.6. Parainfluenza Virus
11.2.1.7. Flu A
11.2.1.8. Others
11.2.2. Bacteria
11.2.2.1. Mycoplasma Pneumoniae
11.2.2.2. Chlamydophila Pneumonia
11.3. Market Value Forecast, by Panel Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospital Point-of-Care testing
11.4.2. Ref Laboratories
11.4.3. Hospitals
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.1.1.1. Viruses
11.5.1.1.1.1. Adenovirus
11.5.1.1.1.2. Severe Acute Respiratory Syndrome
11.5.1.1.1.3. RSV
11.5.1.1.1.4. Human Metapneumovirus
11.5.1.1.1.5. Rhinovirus/Enterovirus
11.5.1.1.1.6. Parainfluenza Virus
11.5.1.1.1.7. Flu A
11.5.1.1.1.8. Others
11.5.1.1.2. Bacteria
11.5.1.1.2.1. Mycoplasma Pneumoniae
11.5.1.1.2.2. Chlamydophila Pneumonia
11.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospital Point-of-Care testing
11.5.1.3.2. Ref Laboratories
11.5.1.3.3. Hospitals
11.5.1.3.4. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.2.1.1. Viruses
11.5.2.1.1.1. Adenovirus
11.5.2.1.1.2. Severe Acute Respiratory Syndrome
11.5.2.1.1.3. RSV
11.5.2.1.1.4. Human Metapneumovirus
11.5.2.1.1.5. Rhinovirus/Enterovirus
11.5.2.1.1.6. Parainfluenza Virus
11.5.2.1.1.7. Flu A
11.5.2.1.1.8. Others
11.5.2.1.2. Bacteria
11.5.2.1.2.1. Mycoplasma Pneumoniae
11.5.2.1.2.2. Chlamydophila Pneumonia
11.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospital Point-of-Care testing
11.5.2.3.2. Ref Laboratories
11.5.2.3.3. Hospitals
11.5.2.3.4. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.3.1.1. Viruses
11.5.3.1.1.1. Adenovirus
11.5.3.1.1.2. Severe Acute Respiratory Syndrome
11.5.3.1.1.3. RSV
11.5.3.1.1.4. Human Metapneumovirus
11.5.3.1.1.5. Rhinovirus/Enterovirus
11.5.3.1.1.6. Parainfluenza Virus
11.5.3.1.1.7. Flu A
11.5.3.1.1.8. Others
11.5.3.1.2. Bacteria
11.5.3.1.2.1. Mycoplasma Pneumoniae
11.5.3.1.2.2. Chlamydophila Pneumonia
11.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospital Point-of-Care testing
11.5.3.3.2. Ref Laboratories
11.5.3.3.3. Hospitals
11.5.3.3.4. Others
12. Competitive Landscape
12.1. Market Player –Competition Matrix (By Tier and Size of companies)
12.2. Company Profiles (2020)
12.2.1. F. Hoffmann-La Roche Ltd.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. Financial Overview
12.2.1.4. Strategic Overview
12.2.1.5. SWOT Analysis
12.2.2. bioMerieux SA
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. Financial Overview
12.2.2.4. Strategic Overview
12.2.2.5. SWOT Analysis
12.2.3. Medline Industries, Inc.
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. Strategic Overview
12.2.3.4. SWOT Analysis
12.2.4. Becton, Dickinson & Company
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. Financial Overview
12.2.4.4. Strategic Overview
12.2.4.5. SWOT Analysis
12.2.5. altona Diagnostics GmbH
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. Strategic Overview
12.2.5.4. SWOT Analysis
12.2.6. CerTest Biotec S.L.
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. Strategic Overview
12.2.6.4. SWOT Analysis
12.2.7. Anatolia Geneworks
12.2.7.1. Company Overvie



List of Figures

 

Figure 01: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Panel Specimen Type, 2020

Figure 03: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Specimen Type, 2020

Figure 04: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by End-user, 2020

Figure 05: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Region, 2020

Figure 06: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 07: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 08: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Viruses, 2017–2031

Figure 09: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Bacteria, 2017–2031

Figure 10: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 11: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 12: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

Figure 13: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Low Plex Panel, 2017–2031

Figure 14: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 15: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 16: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospital Point-of-Care Testing, 2017–2031

Figure 17: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Ref Laboratories, 2017–2031

Figure 18: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 19: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Others, 2017–2031

Figure 20: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Analysis, 2020 and 2031

Figure 21: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Region, 2021–2031

Figure 22: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 23: Europe Respiratory Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

Figure 24: Europe Respiratory Panel Testing Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 25: Europe Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 26: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 27: Europe Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 28: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 29: Europe Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 30: Europe Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 31: Germany Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 32: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 33: Germany Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 34: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 35: Germany Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 36: Germany Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 37: U.K. Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 38: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 39: U.K. Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 40: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 41: U.K. Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 42: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 43: France Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 44: France Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 45: France Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 46: France Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 47: France Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 48: France Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 49: Italy Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 50: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 51: Italy Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 52: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 53: Italy Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 54: Italy Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 55: Spain Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 56: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 57: Spain Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 58: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 59: Spain Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 60: Spain Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 61: Sweden Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 62: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 63: Sweden Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 64: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 65: Sweden Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 66: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 67: Denmark Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 68: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 69: Denmark Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Figure 70: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

Figure 71: Denmark Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 72: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 73: Finland Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

Figure 74: Finland Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

Figure 75: Finland Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

List of Tables


Table 01: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 02: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 03: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 04: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 05: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 09: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 10: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 11: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 12: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 14: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 15: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 16: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 17: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 19: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 20: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 21: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 22: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 23: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 24: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 25: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 26: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 27: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 28: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 29: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 30: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 31: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 32: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 34: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 35: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 36: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 37: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 38: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 39: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 40: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 41: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 42: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 43: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 44: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 45: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 46: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 47: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 49: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 50: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 51: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 52: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 53: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 54: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 55: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 56: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 57: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 59: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 60: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 61: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 62: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 63: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 64: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 65: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 66: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 67: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 68: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 69: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 70: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

Table 71: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

Table 72: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 73: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

Table 74: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

Table 75: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031